# Inhibrx Biosciences Inc. – FDA 483, Jul 2, 2026

Source: https://www.keypedia.com/records/483/inhibrx-biosciences-inc/b72a5b67-10f7-4f17-b7a1-efe407156f53

> FDA 483 for Inhibrx Biosciences Inc. on July 02, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Inhibrx Biosciences Inc.
- Inspection Date: 2026-07-02
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Inhibrx Biosciences Inc. in La Jolla, CA, identified multiple deficiencies in their role as a clinical trial sponsor. Observations included failures in proper study monitoring, ensuring accurate data, timely reporting of serious adverse events, and prompt communication of study results to investigator sites. These issues highlight significant lapses in oversight and adherence to protocol requirements during clinical investigations.

## Related Officers

- [Samson O. Oluseye](https://www.keypedia.com/people/samson-o-oluseye/bfe102f5-25cb-4ed9-9e69-2ec5ec0a047f)

Company: https://www.keypedia.com/companies/inhibrx-biosciences-inc/d13e278b-a848-4ac6-bfdc-3bf8c67f52d9

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6